#ACR19 Abst#2728 Plenary: Upadacitinib RCT in AnkSpa Improved ASAS40 at wk14 (52% v 26% PLBO, NNT~4) and SPARCC MRI Scores. Good safety profile but too small a trial to assess properly Overall an encouraging result, JAKi impacting yet another disease! @RheumNow https://t.co/GtB9wHuoNp